An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705 (NCT05295433)
A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of this study is to evaluate the long-term safety and clinical activity of mRNA-3705 administered to participants with isolated methylmalonic acidemia (MMA) due to methylmalonyl-coenzyme A mutase (MUT) deficiency who have previously participated in other clinical studies of mRNA-3705.
Who can join: Review the eligibility criteria below.
Location: UCLA Medical Center — Los Angeles, California
Age range: 1 Year
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- UCLA Medical Center — Los Angeles, California
- Lucile Packard Children's Hospital at Stanford — Palo Alto, California
- Altman Clinical and Translational Research Institution — San Diego, California
- Stollery Children's Hospital University of Alberta — Edmonton, Alberta
- Hospital For Sick Children — Toronto, Ontario
- Hôpital Necker - Enfants Malades APHP — Paris,
- Erasmus MC — Rotterdam,
- Universitair Medisch Centrum Utrecht — Utrecht,
- Hospital Universitario Cruces — Barakaldo, Vizcaya
- Hospital Universitario 12 de Octubre — Madrid,
- Birmingham Children's Hospital NHS Foundation Trust — Birmingham,
- Royal Manchester Childrens Hospital — Manchester,
📞 Contact the Study Coordinator
Phone: (866) 663-3762
Email: WeCareClinicalTrials@modernatx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Methylmalonic Acidemia
- Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy — Atlanta, Georgia
Explore by condition: All Methylmalonic Acidemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.